JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy

被引：19
|
作者：
Gangat, Naseema [1 ]
Szuber, Natasha [2 ]
Alkhateeb, Hassan [1 ]
Al-Kali, Aref [1 ]
Pardanani, Animesh [1 ]
Tefferi, Ayalew [1 ]
机构：
[1] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN 85259 USA
[2] Univ Montreal, Dept Hematol, Montreal, PQ, Canada
来源：
BLOOD | 2021年 / 138卷 / 26期
关键词：
MECHANISM;
D O I：
10.1182/blood.2021013996
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2886 / 2889
页数：4
相关论文
共 50 条
  • [41] Individual and social determinants of adherence to sodium-glucose cotransporter 2 inhibitor therapy: A trajectory analysis
    Yang, Lanting
    Gabriel, Nico
    Bian, Jiang
    Bilello, Lori A.
    Wright, Davene R.
    Hernandez, Inmaculada
    Guo, Jingchuan
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (11): : 1242 - 1251
  • [42] Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan
    Igarashi, Ataru
    Maruyama-Sakurai, Keiko
    Kubota, Anna
    Akiyama, Hiroki
    Yajima, Toshitaka
    Kohsaka, Shun
    Miyata, Hiroaki
    DIABETES THERAPY, 2022, 13 (07) : 1367 - 1381
  • [43] Severe Vulvovaginal Candidiasis Associated With Sodium-Glucose Cotransporter 2 Inhibitor Use in Postmenopausal Women
    Miao, Vera Y.
    Wijaya, Marlene
    Fischer, Gayle
    Saunderson, Rebecca B.
    JOURNAL OF LOWER GENITAL TRACT DISEASE, 2024, 28 (04) : 371 - 376
  • [44] Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
    Scheen, Andre J.
    NATURE REVIEWS ENDOCRINOLOGY, 2020, 16 (10) : 556 - 577
  • [45] Case of sodium-glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis
    Yeoh, Huei Li
    Lee, Marilyn
    Pan, Woei Jack
    Ong, Hean Yee
    BMJ CASE REPORTS, 2021, 14 (08)
  • [46] Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
    Vivian, Eva
    DIABETES EDUCATOR, 2015, 41 : 5S - 18S
  • [47] Baseline Characteristics Associated With Sodium-Glucose Cotransporter Inhibitor Prescriptions in Type 2 Diabetic Patients in Jazan, Saudi Arabia
    Somaili, Mohammed
    Oraibi, Omar
    Mohrag, Mostafa
    Hommadi, Abdelrahman
    Moafa, Esam
    Kulaybi, Abdulrahman
    Shobayli, Sahar
    Moafa, Razan
    Mhgfory, Ghadah
    Jaafari, Afaf
    Shami, Ayman
    Majrashi, Khalid
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (04)
  • [48] Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes
    Ingelfinger, Julie R.
    Rosen, Clifford J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22): : 2178 - 2179
  • [49] The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes
    Steen, Oren
    Goldenberg, Ronald M.
    CANADIAN JOURNAL OF DIABETES, 2017, 41 (05) : 517 - 523
  • [50] Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
    Neal, Bruce
    Perkovic, Vlado
    de Zeeuw, Dick
    Mahaffey, Kenneth W.
    Fulcher, Greg
    Ways, Kirk
    Desai, Mehul
    Shaw, Wayne
    Capuano, George
    Alba, Maria
    Jiang, Joel
    Vercruysse, Frank
    Meininger, Gary
    Matthews, David
    DIABETES CARE, 2015, 38 (03) : 403 - 411
12345